- Home
- ROMA vs TLSI Comparison
ROMA vs TLSI Comparison
Compare ROMA & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROMA
- TLSI
- Stock Information
- Founded
- ROMA 2018
- TLSI 2010
- Country
- ROMA Hong Kong
- TLSI United States
- Employees
- ROMA N/A
- TLSI N/A
- Industry
- ROMA Savings Institutions
- TLSI Medical Specialities
- Sector
- ROMA Finance
- TLSI Health Care
- Exchange
- ROMA Nasdaq
- TLSI Nasdaq
- Market Cap
- ROMA 150.7M
- TLSI 150.0M
- IPO Year
- ROMA 2024
- TLSI N/A
- Fundamental
- Price
- ROMA $3.31
- TLSI $4.73
- Analyst Decision
- ROMA
- TLSI Strong Buy
- Analyst Count
- ROMA 0
- TLSI 5
- Target Price
- ROMA N/A
- TLSI $10.90
- AVG Volume (30 Days)
- ROMA 47.5K
- TLSI 103.4K
- Earning Date
- ROMA 09-25-2025
- TLSI 11-13-2025
- Dividend Yield
- ROMA N/A
- TLSI N/A
- EPS Growth
- ROMA N/A
- TLSI N/A
- EPS
- ROMA N/A
- TLSI N/A
- Revenue
- ROMA $1,568,345.00
- TLSI $35,990,000.00
- Revenue This Year
- ROMA N/A
- TLSI $56.79
- Revenue Next Year
- ROMA N/A
- TLSI $54.15
- P/E Ratio
- ROMA N/A
- TLSI N/A
- Revenue Growth
- ROMA 23.21
- TLSI 45.50
- 52 Week Low
- ROMA $0.54
- TLSI $3.42
- 52 Week High
- ROMA $4.66
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- ROMA 54.30
- TLSI 51.40
- Support Level
- ROMA N/A
- TLSI N/A
- Resistance Level
- ROMA $3.40
- TLSI $5.10
- Average True Range (ATR)
- ROMA 0.33
- TLSI 0.26
- MACD
- ROMA 0.01
- TLSI -0.23
- Stochastic Oscillator
- ROMA 97.38
- TLSI 88.69
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.